Phase I Study of H5.020CMV.PDGF-β to Treat Venous Leg Ulcer Disease

Autor:	David J. Margolis, Sachin S Vaikunth, Maryte Papadopoulos, Stephanie A Lang, Linda Weinberg, Timothy M. Crombleholme, Jennifer C. Filip, Lee M Morris
Rok vydání:	2009
Předmět:	Adult Male medicine.medical_specialty Platelet-derived growth factor Genetic Vectors Cytomegalovirus Neovascularization Physiologic Disease Venous leg ulcer Adenoviridae Varicose Ulcer Neovascularization 030207 dermatology & venereal diseases 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Drug Discovery Genetics medicine Humans Promoter Regions Genetic Molecular Biology 030304 developmental biology Platelet-Derived Growth Factor Pharmacology 0303 health sciences business.industry Leg Ulcer Genetic Therapy Original Articles Middle Aged medicine.disease 3. Good health Phase i study Surgery Clinical trial Enhancer Elements Genetic Treatment Outcome chemistry Molecular Medicine Female Animal studies medicine.symptom business
Zdroj:	Molecular Therapy. 17:1822-1829
ISSN:	1525-0016
DOI:	10.1038/mt.2009.169
Popis:	Venous leg ulcers are a prevalent nonhealing wound of the lower extremity. Although topically applied growth factors successfully improve wound repair in animal studies, similar studies on humans with venous leg ulcers have not been successful. This study was designed to evaluate the acute safety and biologic feasibility of peri-ulcer injection of a replication-incompetent adenoviral construct expressing platelet-derived growth factor-beta (PDGF-beta). In this phase I study, we demonstrate the initial safety, feasibility, and biologic plausibility of using H5.020CMV.PDGF-beta to treat venous leg ulcer disease.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb5cb24b561740ab02c072617ad5d013 https://doi.org/10.1038/mt.2009.169 Zobrazit plný text záznamu